Asia Pacific Motion Sickness Treatment Market

Asia Pacific Motion Sickness Treatment Market Size, Share & Industry Trends Analysis Report By Drug Class (Antihistamines, Anticholinergics and Others), By Route of Administration, By Distribution Channel, By Country and Growth Forecast, 2023 - 2029

Report Id: KBV-15122 Publication Date: April-2023 Number of Pages: 87
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support

Market Report Description

The Asia Pacific Motion Sickness Treatment Market would witness market growth of 3.9% CAGR during the forecast period (2023-2029).

The market should expand as a result of the growing demand for medications that may successfully alleviate the symptoms of motion sickness. This condition is a typical hazard that is connected with extensive foreign travel. In addition, research has found that there is a gender difference in the frequency of motion sickness symptoms in virtual reality (VR), with females experiencing more symptoms than males do. This is because females tend to be more sensitive to motion sickness than males.

The considerable prevalence of motion sickness, particularly among females, is the reason for the projected rise in the demand for anticholinergic and antihistamines medications that inhibit emetic H1-receptors from preventing motion sickness. This is due to the fact that these treatments prevent emetic H1-receptors from activating. Because of this, it is anticipated that the growth of the market will accelerate throughout the time in question.

Moreover, the increasing emphasis of the enterprise on introducing merchandise that addresses and minimizes motion sickness indications is also bolstering market expansion. Introducing a cutting-edge waterproof wearable therapeutic device that provides user-controlled therapy for a range of nausea and vomiting conditions, including those caused by doctor-diagnosed migraines, morning sickness from alcohol withdrawal, anxiety, pregnancy, motion sickness, chemotherapy, and post-operative nausea.

India boasts many natural, historical, cultural, and spiritual treasures. India's spiritual grandeur and heritage attract millions of local and foreign tourists who seek to experience them. Links to sacred or historic locations, people, or events have been instrumental in the growth of several popular tourist destinations, with religion, spirituality, and legacy being significant motivators for travel.

To fully realize the potential of pilgrimage and heritage tourism in India, authorities are striving to integrate development plans for the chosen pilgrimage destinations and heritage cities in collaboration with other stakeholders. Due to these factors, the travel industry in the APAC region is expected to experience growth, and with the rise in tourism, people suffering from motion sickness are expected to increase, which will provide market growth for motion sickness treatment in the region.

The China market dominated the Asia Pacific Motion Sickness Treatment Market by Country in 2022; thereby, achieving a market value of $37.4 Million by 2029. The Japan market is poised to grow at a CAGR of 3.3% during (2023 - 2029). Additionally, The India market would showcase a CAGR of 4.6% during (2023 - 2029).

Based on Drug Class, the market is segmented into Antihistamines, Anticholinergics and Others. Based on Route of Administration, the market is segmented into Oral and Others. Based on Distribution Channel, the market is segmented into Drug Store & Retail Pharmacies, Hospital Pharmacies and Online Pharmacies. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

Free Valuable Insights: The Worldwide Motion Sickness Treatment Market is Projected to reach USD 481 Million by 2029, at a CAGR of 3.2%

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Viatris, Inc., Teva Pharmaceutical Industries Ltd., Amneal Pharmaceuticals, Inc., Baxter International, Inc., Novartis AG, Abbott Laboratories, Sun Pharmaceutical Industries Ltd., Zydus Lifesciences Ltd., Prestige Consumer Healthcare, Inc., WellSpring Pharmaceutical Corporation (Avista Capital Partners).

Scope of the Study

Market Segments Covered in the Report:

By Drug Class

  • Antihistamines
  • Anticholinergics
  • Others

By Route of Administration

  • Oral
  • Others

By Distribution Channel

  • Drug Store & Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

By Country

  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific

Key Market Players

List of Companies Profiled in the Report:

  • Viatris, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Baxter International, Inc.
  • Novartis AG
  • Abbott Laboratories
  • Sun Pharmaceutical Industries Ltd.
  • Zydus Lifesciences Ltd.
  • Prestige Consumer Healthcare, Inc.
  • WellSpring Pharmaceutical Corporation (Avista Capital Partners)
Need a report that reflects how COVID-19 has impacted this market and its growth? Download Free Sample Now


Call: +1(646) 600-5072


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings

  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo